Two decades of commitment to malaria vaccine development: GlaxoSmithKline Biologicals.
GlaxoSmithKline Biologicals (GSK) is committed to the development of a safe and effective malaria vaccine. Its research program in this field was initiated in 1984 and has been continuously active to this day, making it unparalleled within the vaccine industry. Although it works in partnerships with several leading organizations from the public sector, this effort has required GSK to invest major financial and human resource commitments, and its partners rely heavily on the company's global infrastructure and expertise in research, advanced clinical development, regulatory, large-scale manufacturing, and commercialization. Through GSK's pioneering business model and working in partnership with global vaccine funding agencies, the company is committed to seeing that, once approved, a safe and effective malaria vaccine will be available to everyone that needs it.
Ballou
W Ripley
WR
Global Clinical Research & Development, GlaxoSmithKline Biologicals, 89 Rue de l'Institut, Rixensart, Belgium. ripley.ballou@gskbio.com
Cahill
Conor P
CP
D000818:Animals; D004345:Drug Industry; D006801:Humans; D008288:Malaria / Q000469:parasitology / Q000517:prevention & control / Q000628:therapy*; D017780:Malaria Vaccines; D010961:Plasmodium / Q000276:immunology; D012106:Research
D017780:Malaria Vaccines